Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
0.9400
-0.0322 (-3.31%)
At close: Oct 23, 2026, 4:00 PM EDT
0.9524
+0.0124 (1.32%)
After-hours: Oct 23, 2026, 7:55 PM EDT
Company Description
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Imran Alibhai |
Contact Details
Address: 3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States | |
| Phone | 713 489 8654 |
| Website | tvarditherapeutics.com |
Stock Details
| Ticker Symbol | TVRD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001346830 |
| CUSIP Number | 140755307 |
| ISIN Number | US1407553072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Imran Alibhai Ph.D. | Chief Executive Officer and Director |
| Dan Conn J.D., M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. John Kauh M.D. | Chief Medical Officer |
| David J. Tweardy M.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael T. Lewis Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of Research & Development |
| Stephen O'Brien CPA | Vice President of Finance and Corporate Controller |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 424B5 | Filing |
| Jul 7, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |
| May 13, 2026 | EFFECT | Notice of Effectiveness |
| May 12, 2026 | EFFECT | Notice of Effectiveness |
| May 8, 2026 | POS AM | Post-Effective amendments for registration statement |